
Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Oncology Today with Dr Neil Love
00:00
INVIGOR011: Prospective ctDNA‑Guided Atezolizumab
Galsky explains INVIGOR011 design: ctDNA-positive randomization, serial monitoring, and implications for MRD‑guided therapy.
Play episode from 58:40
Transcript


